-

10:01:44 AM

IFRX Stock News

IFRX - InflaRx N.V.

10/19/21 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory

RHEA-AI

very positive

10/12/21 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement

RHEA-AI

neutral

09/09/21 7:30 AM

Nasdaq : IFRX

conferences

InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces that Prof. Niels C. Riedemann, Chief Executive Officer and Founder, will present a company

RHEA-AI

neutral

09/08/21 7:30 AM

Nasdaq : IFRX

InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

InflaRx received feedback from FDA within its Type A meeting which is supportive of a new primary endpoint measuring reductions in all three inflammatory HS lesions – including reductions of draining tunnels (previously referred to as draining fistulas) InflaRx will focus its pivotal development

RHEA-AI

neutral

08/10/21 7:30 AM

Nasdaq : IFRX

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesion Treatment was well tolerated; no adverse events associated with dose escalation Treatment of the third cohort with the 2400 mg dose is ongoing JENA, Germany, Aug.

RHEA-AI

neutral

08/06/21 7:30 AM

Nasdaq : IFRX

conferences

InflaRx to Present at the BTIG Virtual Biotechnology Conference

InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the BTIG Virtual Biotechnology Conference on August 10. A BTIG analyst will host a

RHEA-AI

neutral

08/05/21 7:30 AM

Nasdaq : IFRX

InflaRx Reports Second Quarter 2021 Financial & Operating Results

Severe COVID-19 trial enrollment reaches 299 patients; an independent data monitoring committee has recommended to continue the trial as planned after analyzing data from the first 180 evaluable patients Type A meeting request submitted to further discuss primary endpoint for the Phase III clinical

RHEA-AI

neutral

06/17/21 7:30 AM

Nasdaq : IFRX

conferences

InflaRx to Present at the Raymond James Human Health Innovation Conference

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present virtually at the Raymond James Human Health Innovation Conference being held June

RHEA-AI

neutral

06/08/21 7:30 AM

Nasdaq : IFRX

clinical trial

InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today

RHEA-AI

neutral

05/21/21 7:30 AM

Nasdaq : IFRX

management

Tony Gibney Joins InflaRx Board of Directors

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced Mr. Tony Gibney has been appointed as a Non-Executive Director to the Board of

RHEA-AI

positive

IFRX Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.inflarx.de
Security nameInflaRx N.V.
Issue typecs
SectorManufacturing
Sic code2834
Employees49
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressWinzerlaer Str. 2
StateThueringen
CityJena
Zip07745
CountryGermany
Phone493641508180

IFRX Description:

InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.